ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Business

Shionogi drug can kill viruses in 1 day

OSAKA -- Shionogi & Co. will release what it calls the world's first one-day treatment for influenza in Japan as early as 2018.

     Unlike conventional offerings, the new drug prevents the flu virus from propagating. It inhibits the activity of enzymes that aid the propagation of viruses that enter the body through the throat or nose. The drug is taken orally.

     Current flu treatments include Tamiflu, from Swiss drugmaker Roche. But Tamiflu does not halt the spread of the virus and must be taken for five days or so.

     Shionogi has conducted phase I clinical trials in Japan, testing the drug on healthy people to evaluate its safety. The Japanese company plans to begin phase II trials on hundreds of subjects as early as November, once the flu season begins, to confirm efficacy.

     The health ministry recently put the drug into a fast-track approval process for quickly bringing groundbreaking new treatments to market.

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more